AZ rejected on the Seroquel’s flexible application of PMS cases for children

The flexible application of the post-marketing surveillance(PMS) for the AstraZeneca’s schizophrenia treatment, ‘Seroquel(generic name: quetiapine),’ was rejected. The issue was the number of cases targeting children and the youth.

According to the data unveiled by the Ministry of Food and Drug Safety(MFDS) on the 11^th, the Central Pharmaceutical Deliberation Committee recently decided ‘re-del...